Signals · theoretical, educational setups
Intel's Guidance Gap, Amazon's Cash Test and Lilly's Breakout
Three theoretical setups after the busiest earnings evening of the week: Intel, down about 23% after hours on a fourth-quarter forecast far below estimates; Amazon, which fell after hours despite 39% AWS growth; and Eli Lilly, which rose about 6% after raising its revenue forecast for the third time this year.
INTC · Intel Corporation — Bearish, Short-term (days). Intel closed at $92.07 on October 29 and traded about 21% to 23% lower after hours following its third-quarter report. The quarter itself beat: adjusted earnings of $0.52 a share against about $0.28 expected, revenue of $16.51 billion and data-centre revenue up nearly 80% from a year earlier to $7.3 billion. The forecast did the damage. Intel guided to fourth-quarter revenue of $15 billion to $16 billion and adjusted earnings of about $0.25 a share against roughly $0.43 expected, with gross margin narrowing to 38% from 44.1%, citing PC weakness, memory shortages and a $300 million hit from a plant shutdown in Israel. Binance's tokenised Intel fell 17.4% in the first fifteen minutes, from $92.15 to $76.11, rebounded to $79.19 by 20:30 UTC, then drifted to about $70.60 by Friday morning on heavy volume. A gap driven by guidance rather than by the reported quarter tends to be followed by estimate cuts over the next few sessions, and the failure of the only rebound at $79.19 marks where sellers stepped back in. The risk is that the 2026 rally, which had lifted the stock above $90, leaves room for short-covering if the regular session opens well above the after-hours low. A daily close above $79.19, the post-report rebound high, would invalidate the setup.
AMZN · Amazon.com Inc. — Neutral, Short-term (days). Amazon fell 4.25% to $243.79 in the regular session on October 29, dragged down with Alphabet, and then a further 6.1% to $228.90 after hours on its own report. AWS revenue grew 39% to $46.0 billion, the fastest in nearly five years, and the backlog reached $578 billion, but earnings of $1.89 a share missed the $1.96 forecast, cash capital spending was $75.9 billion in the quarter and the company said it would spend "meaningfully more" in 2027. Binance's tokenised Amazon touched $214.31 in the first quarter-hour after the release, 12.3% below its pre-report level, and spent the night between about $224 and $232. The two forces pull in opposite directions: accelerating cloud growth with a 38.7% operating margin argues that the spending has customers, while free cash flow that TradingKey put at minus $33.5 billion argues that shareholders are funding them. A move of this kind after a report that mixes the two usually needs several sessions of two-way trading before it resolves. The levels define the next move rather than a view: a daily close below $214.31, the after-hours low, would extend the selling into a new range; a close back above $243.79, Thursday's close, would mean the market has accepted the capital budget.
LLY · Eli Lilly and Company — Bullish, Short-term (days). Eli Lilly rose about 6% on October 29 after reporting third-quarter revenue up 39% to $24.4 billion, led by Mounjaro and Zepbound, and raising its 2026 revenue forecast for the third time this year, to $91 billion to $92 billion from $85 billion to $87 billion. Adjusted earnings of $7.48 a share were well above the roughly $5.38 consensus even after $4.57 a share of acquired research charges, which also explain why the full-year earnings range was trimmed to $35 to $36. The move came on a day when most of the S&P 500 rotated into health care and away from technology, which gives it a sector tailwind as well as a company-specific one. Binance's tokenised Lilly, which trades thinly, jumped from about $1,317 to $1,347 in the quarter-hour of the 6:45 a.m. ET release, reached $1,407.31 in the first fifteen minutes of the regular session and then held between about $1,362 and $1,394 into Friday. A gap on a guidance raise that holds most of its gain through the session usually attracts follow-through as analysts lift targets. The risk is the obesity-pill line: CNBC reported that sales of Foundayo, launched in April, were below Wall Street's expectations. A daily close below $1,327.89, the low of the opening fifteen minutes, would invalidate the setup.